04th March 2022 | Pharma Updates
Moral Group has launched their own Pharma Consultancy Application
Moral Group of Companies, a 15-year-old trusted name, has announced the launch of their own online pharma application, which will allow patients to simply order all of their medical needs in one spot.
Local drug companies are in a bind due to RDIF sanctions
Due to sanctions imposed by the US, UK, and EU, Indian drug manufacturers who have signed up with the Russian sovereign fund RDIF to manufacture the Sputnik vaccine are in a quandary.
Merck's COVID pill is recommended by the WHO for high-risk patients
The World Health Organization’s expert panel conditionally advised molnupiravir for patients with non-severe disease who are at high risk of hospitalisation, such as the immunocompromised, the unvaccinated, the elderly, and those with chronic disorders.
Mocravimod has been designated an orphan medication by the FDA for the treatment of acute myeloid leukaemia
The FDA designated mocravimod as an orphan medication for the treatment of patients with acute myeloid leukaemia who are undergoing allogeneic hematopoietic stem cell transplantation.
Zentiva to contribute 100,000 medical kits to the Ukrainian humanitarian crisis
The Company is collaborating with governmental organisations and nongovernmental organisations to respond to urgent requests from the Ukrainian government and Ukrainian citizens crossing into the EU.
CTI Biopharma's Vonjo has been approved by the FDA for the treatment of rare bone marrow disorders
FDA has granted fast approval to CTI BioPharma’s Vonjo (pacritinib) for the treatment of people with intermediate- or high-risk myelofibrosis, which are rare types of bone marrow abnormalities.
In a safety study, the Redhill antiviral showed promise; the J&J injection was less effective in reducing hospitalisation
A large French study found that the risk of hospitalisation after vaccination with J&J’s COVID-19 vaccine, and an experimental oral drug being developed by Redhill Biopharma Inc interrupts a process that helps the coronavirus infect cells.
TNX-2900 has been designated as an orphan drug by the FDA for the treatment of PraderWilli syndrome
Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that the FDA has given Orphan-Drug Designation for TNX-2900* (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4- 1BB Bispecific Antibody TJ-CD4B
“The Orphan Drug Designation demonstrates the FDA’s acknowledgement of TJ-potential CD4B’s promise as a novel therapy for gastric cancer and other associated tumours, ” stated I-Mab President.
FDA has approved Purdue Pharma's Nalmefene Hydrochloride Injection to treat opioid overdoses
“Nalmefene will be an important therapeutic option to address the opioid problem, which has intensified during the COVID-19 pandemic and is being exacerbated by the increasing frequency of illicitly made synthetic opioids, ” the company said.
